{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:26:00Z","timestamp":1761128760591},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/rhu.0b013e3181b0d352","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T07:32:03Z","timestamp":1249371123000},"page":"267","source":"Crossref","is-referenced-by-count":8,"title":["Resolution of Rheumatoid Arthritis Symptoms With Imatinib Mesylate"],"prefix":"10.1097","volume":"15","author":[{"given":"Matthew R.","family":"Vernon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-19-20210207","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/RHU.0b013e318188b1ce","article-title":"Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.","volume":"14","author":"Eklund","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R2-19-20210207","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","article-title":"Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.","volume":"116","author":"Paniagua","year":"2006","journal-title":"J Clin Invest"},{"key":"R3-19-20210207","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/rheumatology\/kel365","article-title":"Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients.","volume":"45","author":"Eklund","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R4-19-20210207","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00774-006-0684-1","article-title":"Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA).","volume":"24","author":"Ando","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"R5-19-20210207","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-007-0592-9","article-title":"Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.","volume":"17","author":"Koyama","year":"2007","journal-title":"Mod Rheumatol"},{"key":"R6-19-20210207","first-page":"2304","article-title":"Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation.","volume":"25","author":"Ceponis","year":"1998","journal-title":"J Rheumatol"},{"key":"R7-19-20210207","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-065X.2007.00504.x","article-title":"Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.","volume":"217","author":"Eklund","year":"2007","journal-title":"Immunol Rev"},{"key":"R8-19-20210207","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/ard.2004.029835","article-title":"Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.","volume":"64","author":"Juurikivi","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R9-19-20210207","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4161\/cc.4.7.1788","article-title":"Inhibition of c-fms by imatinib: expanding the spectrum of treatment.","volume":"4","author":"Dewar","year":"2005","journal-title":"Cell Cycle"},{"key":"R10-19-20210207","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2006.06.052","article-title":"Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts.","volume":"347","author":"Sandler","year":"2006","journal-title":"Biochem Biophys Res Commun"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e3181b0d352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:54:28Z","timestamp":1620971668000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-200908000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e3181b0d352","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}